New Canadian research has found that having a D supplement could help slow down the progression of type 2 diabetes with those who’ve been recently diagnosed with the condition, or those who show signs of prediabetes.
Led by researchers at the Université Laval in Quebec, the brand new small-scale study looked at 96 participants who were either newly clinically recognized as having type 2 diabetes or at high risk of developing the condition, a disorder generally known as prediabetes, that can be identified by several risk factors such as obesity or perhaps a family history of the disease.
Less participants were arbitrarily assigned to receive a high dose of vitamin D3 (5000 iu, which happens to be approximately about 10 times the recommended dose) once daily for six months, while the better half were assigned to receive a daily placebo. The scientists measured markers of insulin function and glucose metabolism before and once the six months.
The findings, published in the European Journal of Endocrinology, revealed that vitamin D levels were substantially higher within the group who had taken a complement in comparison with those who had taken the placebo. In addition, taking vitamin D supplements appeared to significantly improve the action of insulin within the muscle tissue of participants after 6 months.
Preceding Research has suggested that low d levels really are a risk factor for developing diabetes type 2. However, research studiesinvestigating whether vitamin D supplementation can change metabolic function have produced inconsistent outcomes. The scientists say this could be due to a low number of study participants, or because participants with normal vitamin D levels at the start were metabolically healthy or had been existing with diabetes type 2 for a long period of time.
Study researcher Dr. Claudia Gagnon commented, “The reason we saw improvements in glucose metabolism following d supplementation with those at higher risk of diabetes, or with newly diagnosed diabetes, while other studies didn’t demonstrate an impact in people with long-standing diabetes type 2 is unclear. This could be mainly because that improvements in metabolic function are harder to detect in those with longer-term disease or that the longer treatment time is needed to see the benefits.”
She recommends further studies to enquire how different people reply to d supplementation and if the constructive effect on metabolism present in this study can be maintained in the longer term.
“Diabetes type 2 and prediabetes really are a growing public health concern and although our results are promising, further studies will be needed to confirm our findings, to identify whether some individuals may benefit more out of this intervention, and to evaluate the safety of high-dose vitamin D supplementation again and again. In the meantime I would recommend that current vitamin D supplementation recommendations be followed,” said Gagnon.